Celebrating 25 years Est 1999-2024
*Across 3 years $2276.64 only $796.82
AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage...
Worldwide revenue of $115.9 million – an increase of 17.9% year over year U.S. revenue of $95.5 million – an increase of 16.8% year over year...
Une approbation qui sert de nouveau vecteur de croissance à l'international pour AtriCure AtriCure, Inc. ( Nasdaq: ATRC ), leader en matière...
Die Zulassung ist ein neuer Katalysator für das internationale Wachstum von AtriCure AtriCure, Inc. (Nasdaq: ATRC), ein führender Innovator im...
Approval provides new catalyst for AtriCure’s international growth AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments and...
Une indication élargie avec abondance de preuves cliniques à l'appui pour les dispositifs AtriClip AtriCure, Inc. ( Nasdaq : ATRC ), l'un des...
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.